Abcam, ab248010, Anti-SKP2 antibody [EPR3306(2)] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal SKP2 antibody. Carrier free. Suitable for ICC/IF, WB and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR3306(2),
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:ICC/IF, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab248010 is the carrier-free version of
ab124799
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
S-phase kinase-associated protein 2 (SKP2) also known as FBL1 or p45 is an E3 ubiquitin ligase that tags proteins for degradation. It weighs around 48 kDa. SKP2 facilitates the transition from the G1 to S phase of the cell cycle by targeting cyclin-dependent kinase inhibitors for proteasomal destruction. Expressed in various tissues including key roles in proliferating cells SKP2 ensures the regulation of cell cycle progression and stability.
Biological function summary
SKP2 is part of the SCF (SKP1-CUL1-F-box) complex which is instrumental in controlling cell cycle and cell division. It regulates the degradation of p27^Kip1 and other cell cycle regulators. By modulating proteolysis SKP2 contributes to the maintenance of cell proliferation and it has essential roles in cellular responses to growth signals. Moreover SKP2 influences processes such as DNA replication through its effect on substrate interaction and ubiquitination.
Pathways
SKP2 functions inside the ubiquitin-proteasome system and impacts the PI3K/AKT signaling pathway. SKP2 advances cell cycle progression by associating with proteins like p27^Kip1 and CDK2 facilitating cell division. It modulates the phosphorylation state of numerous targets influencing signaling processes that control cell growth. This involvement aligns SKP2 with key cellular pathways that maintain cell survival and metabolic balance.
SKP2 plays an important role in cancer and cardiovascular diseases. In various cancers the aberrant expression of SKP2 connects to excessive cell proliferation and tumor growth partially through interactions with oncoproteins like Myc. In cardiovascular conditions SKP2 influences cardiac hypertrophy and might link to proteins such as cyclin-dependent kinase inhibitors. The regulation by SKP2 affects these proteins' stability impacting disease progression and potential therapeutic interventions.